Valeant Pharmaceuticals (VRX.TO) Buy, Sell or…

Home

Daily Stock Opinions and Ratings

Valeant Pharmaceuticals (VRX.TO)

0.00

-0.00 (0.00%)

39 watching

DON'T BUY

A “Buyer Beware” stock. Has only made money through acquisitions.

DON'T BUY

Has always been a controversial company. They don't report true gap numbers. A cash-eating machine. Two principal drugs should do well.

DON'T BUY

The chart indicates the stock is in a very dangerous area.

TOP PICK

It took such a big drop; there should easily be a rebound to $42/$43 area. There are some questions about the company so this is not an investment, but a quick trade.

STRONG BUY

A classic story of an opportunity. It's close to 10 times earnings now. There should be an interesting rebound.

SELL

Doesn't know enough about the issues surrounding their accounting practices. There is also a question mark about prescription sales of Welbutrin.

DON'T BUY

Have never owned because it always traded at too high a multiple. Earnings are not easy to understand.

TOP PICK

A good entry point. Expect better numbers in the fourth quarter.

DON'T BUY

They are going to miss on the quarter. It's not only the earnings that are going down, but the multiples on the earnings as well. A “show me” stock. Could be flat for a while.

DON'T BUY

Problems would suggest that you wait for a while. Would prefer to buy on the way up rather than on the way down.

DON'T BUY

A profitable company. Will be volatile over the next little while. Expected to be in the penalty box for couple of months.

DON'T BUY

Doesn't like the way the key generic businesses have been deteriorating. Technical chart does not look good. Prefers other things in the healthcare sector.

DON'T BUY

Seems to have perpetual rumours that they are going to warn or will be called on for aggressive accounting issues in spite of recent successful product introductions. Not trading at a high valuation. There could be 10/15% downside.

DON'T BUY

A very aggressive company, so this makes it volatile. Not sure that they are adding long-term value to the company. Too risky from their perspective.

DON'T BUY

A fairly expensive stock. Biovale tends to take existing drugs/pharmaceuticals and re-engineers them as new products for the marketplace. Risky. A pretty high price for that system. ROE is not quite that high. Prefers others.

Showing 511 to 525 of 714 entries

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Keith Richards

ValueTrend Wealth Management

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Valeant Pharmaceuticals (VRX.TO)